Protalix BioTherapeutics (PLX)

• Market cap: $186M
• 1 day: -0.86%
• 5 days: -1.28%
• 1 month: -1.7%
• 3 months: 8.96%
• 6 months: 11.59%
• Year to date: 32.76%
• 1 year: 58.22%
• 5 years: 48.08%
• 10 years: -64.24%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Employees: 226